19 November, 2024Women's Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment
30 October, 2024Noema Pharma announces first patients dosed in Phase 2b study with Gemlapodect (NOE-105), a first-in-class investigational therapy for Tourette Syndrome
17 October, 2024Noema Pharma Announces NOE-105 (gemlapodect) Phase 2a Study in Tourette Syndrome met Primary and all Key Secondary Endpoints